- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
Population: Children (1-11 years)
- General population
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Community
- Household
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Emergency department
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Emergency department
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Blood sample
- Nasopharyngeal swab
- Nasal lining fluid sample
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Primary care
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Human metapneumovirus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- Human metapneumovirus infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- Non-hospital health centre
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Adenovirus
- Metapneumovirus
- Parainfluenza Virus
- Rhinovirus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- Adenovirus infection
- Metapneumovirus infection
- Parainfluenza virus infection
- Rhinovirus infection
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- Intensive care unit
- Respiratory syncytial virus
- Respiratory syncytial virus infection